CVS logo

CVS Health

CVS · What the business does, what can go wrong, and how options sellers approach it

What it does

CVS Health is a U.S. healthcare company with several connected businesses. It runs a large chain of retail pharmacies, a pharmacy benefit manager (PBM) called Caremark, and a major health insurer, Aetna. It also offers primary care and other care delivery services.

Most people know CVS for the drugstore on the corner. Much of the business happens out of sight, in insurance plans and in the negotiation of drug prices.

How it makes money

  • Health insurance: Aetna collects premiums from individuals, employers and government programs, then pays medical claims.
  • Pharmacy benefit management: Caremark manages drug coverage for employers and insurers. It earns fees and spreads tied to negotiating with drugmakers and processing prescriptions.
  • Retail pharmacy: Stores earn money from filling prescriptions and selling front-of-store goods. They also provide services such as vaccinations.
  • Care delivery: Clinics and primary care offerings earn fees for patient services.

Why investors own it

Investors often see CVS as a way to own broad exposure to healthcare spending, which tends to be less tied to the economic cycle. The company's businesses can feed each other, such as an insured member using a CVS pharmacy and a CVS-managed drug plan. It has also paid a dividend, which some income-focused investors value.

What can go wrong

  • Medical costs can rise faster than the premiums Aetna has already priced.
  • Government payment rates for Medicare and Medicaid plans can change.
  • PBMs face political and regulatory scrutiny over how they set prices and earn money.
  • Retail pharmacy is competitive, and reimbursement pressure squeezes margins.
  • Combining many business lines is complex, and integration may not deliver the benefits expected.

What to watch

  • Medical benefit ratio (share of premiums spent on care)
  • Medicare Advantage enrollment and government rate announcements
  • Prescription volumes at pharmacies and in Caremark
  • Same-store pharmacy sales
  • PBM regulation and legislation
  • Company guidance updates
  • Dividend and debt reduction commentary

Options income angle

Options on CVS are typically liquid, with many strikes and expirations available. Implied volatility tends to rise around quarterly earnings, guidance changes, government payment rate announcements and policy news on PBMs or drug pricing. A caution for premium sellers: health insurers can move sharply on a single surprise about medical costs or regulation, so a covered call can cap gains in a rally and a short put can lead to a large loss in a sudden drop.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 10, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

CVS Health grew revenue but earned far less in 2025. Net income attributable to the company fell to $1,768 million from $4,614 million, mainly because of a $5,725 million goodwill impairment (a write-down of the value paid for past acquisitions) on its primary care and health services business and about $1.2 billion of legacy litigation charges. The insurance segment, Health Care Benefits, recovered strongly, while the clinic business remains under pressure.

How the business did

  • Total revenues were $402,067 million, up 7.8% from $372,809 million. Operating income fell 45.3% to $4,660 million from $8,516 million.
  • The drop came from the $5,725 million Health Care Delivery goodwill impairment and approximately $1.2 billion of legacy litigation charges tied to two court decisions. A $320 million opioid litigation charge and $288 million of losses on Accountable Care assets also contributed.
  • Health Care Benefits adjusted operating income (the segment profit measure management uses, which excludes items such as intangible amortization) rose to $2,939 million from $307 million. Its medical benefit ratio, the share of premiums spent on medical costs, improved to 91.2% from 92.5%. Pharmacy & Consumer Wellness revenue rose 11.9%, with pharmacy same store sales up 18.0%, helped by drug mix including branded GLP-1 drugs. Health Services adjusted operating income was $7,151 million versus $7,243 million.
  • Net cash provided by operating activities was $10,639 million versus $9,107 million. The company repurchased no shares in 2025 and kept its quarterly dividend at $0.665 per share.

Risks specific to this company

  • Medical cost forecasting: Premiums are set months ahead, so cost overruns cannot be recovered within the policy year. The company recorded premium deficiency reserves (set aside when expected losses exceed premiums) of $448 million for its individual exchange product in the first quarter of 2025 and $471 million for Group Medicare Advantage in the second quarter.
  • Medicare payment and oversight: Proposed 2027 Medicare Advantage rates would raise industry revenue by 2.54%, which includes a risk score trend increase of 2.45%. Without that trend, the increase is 0.09%. CMS also said it would audit every Medicare Advantage contract each payment year.
  • Health Care Delivery goodwill: After the charge, the unit's fair value equaled its carrying value. It still holds approximately $4.2 billion of goodwill, and the filing says another material impairment is reasonably possible in the near term.
  • Litigation: The company is a defendant in hundreds of opioid and talc proceedings. Opioid litigation settlement obligations total $3,975 million. A jury also found Omnicare liable under the federal False Claims Act.
  • PBM regulation: Pharmacy benefit manager (PBM) legislation has been proposed or enacted in a majority of states. Some states have considered banning pharmacy licensure for pharmacies affiliated with a PBM, and several state laws limiting PBM practices face lawsuits.
  • Credit ratings: Long-term debt is rated Baa3 by Moody's and BBB by S&P and Fitch, with a Negative outlook at S&P and Fitch. Long-term debt obligations total $63,709 million.

What management is watching

  • Utilization of medical services is expected to stay elevated in 2026, and anything beyond that level may pressure Health Care Benefits and the health care delivery assets.
  • Management plans to open fewer new primary care clinics in 2026 and after, and to close certain Oak Street Health clinics in 2026. The company exited the Aetna individual exchange states effective January 2026.
  • PBM clients keep taking a larger share of rebates and fees, and pricing guarantees are hard to meet. Management expects these trends to continue.
  • The final 2027 Medicare Advantage rate announcement is due by April 6, 2026. Management also points to star ratings, which now cover more than 81% of Medicare Advantage members in plans rated 4.0 stars or higher, down from 88% the year before.
  • Management directs investors to adjusted operating income, medical benefit ratio, medical membership, prescriptions filled and same store sales. It expects to keep the quarterly dividend of $0.665 per share throughout 2026, and gross capital expenditures were approximately $2.8 billion.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

CVS Health swung to a profit in the third quarter of 2026, mainly because the prior-year quarter carried a $5.7 billion goodwill impairment charge (a write-down of the value of past acquisitions) that did not repeat. Underlying results also improved, led by the Health Care Benefits (Aetna) segment. On November 4, 2026, the company announced it intends to separate into two independent, publicly traded companies.

How the business did

  • Quarter: Total revenues increased $5.5 billion, or 5.4%, driven by Health Services and Health Care Benefits. Operating income was $3.6 billion, versus an operating loss of $3.2 billion a year earlier. Net income attributable to CVS Health was $2,172 million, versus a net loss of $3,975 million. Adjusted operating income, the measure management uses to judge segments, was $4,194 million versus $3,459 million.
  • Year to date: Total revenues rose 6.3%. Operating income increased $10.4 billion, helped by the absence of last year's goodwill impairment and $1.2 billion of legacy litigation charges.
  • Segments: Health Care Benefits adjusted operating income was $912 million versus $314 million. Its medical benefit ratio (the share of premiums paid out for medical care) fell to 91.3% from 92.8%, on better Government business performance. Health Services revenue rose 9.5% on drug mix and brand inflation, with adjusted operating income of $2,106 million versus $2,050 million. Pharmacy & Consumer Wellness revenue fell 2.0%, but adjusted operating income rose to $1,635 million from $1,478 million.
  • Unusual item: The company recorded a contingent guarantee liability tied to resolving Omnicare litigation and bankruptcy matters. The adjusted figures exclude $193 million for it.
  • Cash and capital return: Net cash provided by operating activities for nine months was $15,318 million versus $7,249 million, helped by timing of receipts and payments. The company bought back no shares in the nine months and declared a quarterly dividend of $0.665 per share.

What management is watching

  • Medical costs: Utilization of care stayed elevated in the quarter. Utilization above current levels may pressure Health Care Benefits and the health care delivery assets in Health Services in 2026.
  • Medicare Advantage: More than 69% of Medicare Advantage members are in plans with 2027 star ratings of at least 4.0, versus more than 81% for 2026 ratings. Plans rated four stars or higher qualify for bonus payments.
  • Pharmacy economics: The company expects to keep sharing more rebates with clients, to face manufacturer pressure over rebates, and to see limits on retail network "spread" pricing. It also flags state and federal PBM (pharmacy benefit manager) legislation and weaker front store spending.
  • Separation: The split is expected to be completed in the first half of 2028.

New or changed risks

  • Management distraction: Executing the separation will take significant time and attention from senior management and employees. That could disrupt the business and hurt results.
  • Timing and completion: The separation depends on conditions including board approval, an effective Form 10 registration statement and required consents. The company says there is no assurance it will close on the announced terms or timeline, or at all.
  • Tax treatment: The deal is intended to be tax-free, but the filing warns it may not qualify for that treatment.
  • Costs and benefits: Dis-synergy costs (extra costs from operating separately) and restructuring costs could exceed estimates. The expected benefits may not arrive on time or at all.

Follow CVS in Kortex

The Kortex app shows CVS's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.